Got $200? 2 Dividend Stocks to Buy and Hold Forever

Industry Overview - The global pharmaceutical industry is valued at $1.4 trillion and is expected to grow at an annual rate of 6.1$56.7 billion in sales at their peak in 2022 [3] - Pfizer is focusing on its oncology pipeline for future growth, following its $43 billion acquisition of Seagen in 2023 [4] - Analysts expect Pfizer to grow earnings by an average of 14% annually over the next three to five years [4] - The stock offers a dividend yield of 6.3% with a strong payout ratio of 57% of earnings [5] - Pfizer's stock is valued at less than 10 times forward earnings estimates, indicating potential for double-digit total investment returns [5] Johnson & Johnson (JNJ) - Johnson & Johnson is a diversified healthcare company with a strong pharmaceutical core and a MedTech segment [6] - The company spun off its consumer products business as Kenvue in August 2023 [6] - Johnson & Johnson is a Dividend King with 62 consecutive annual dividend increases [6] - The company's growth is driven by innovation, acquisitions, and share repurchases, resulting in slow but steady earnings growth [7] - Johnson & Johnson's stock trades at a forward P/E ratio of just over 13, with analysts expecting 5% to 6% annualized long-term earnings growth [8] - The stock offers a 3.5% dividend yield and is expected to produce 6% to 10% annualized returns, making it a reliable long-term investment [8]